Mesoblast

Mesoblast EBITDA per Employee

The EBITDA per Employee of Mesoblast (MESO) as of Oct 22, 2026 is -632,716.05 USD. In the previous year, EBITDA per Employee was -770,901.23 USD — a change of -17.93% (higher).

EBITDA per Employee

-632,716.05USD

YoY

-17.93%

Last updated:

EBITDA per Employee of Mesoblast is 2026 -632,716.05 USD. EBITDA per Employee of Mesoblast was 2025 -770,901.23 USD. It decreases by -17.93% higher compared to the previous year.

The Mesoblast EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-1.07 M USD
Jan 1, 2020
-896,777.78 USD
Jan 1, 2021
-1.10 M USD
Jan 1, 2022
-999,419.75 USD
Jan 1, 2023
-775,432.10 USD
Jan 1, 2024
-855,716.05 USD
Jan 1, 2025
-770,901.23 USD
Jan 1, 2026
-632,716.05 USD
The Mesoblast EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-632,716.05USD-17.93%
-770,901.23USD-9.91%
-855,716.05USD+10.35%
-775,432.10USD-22.41%
-999,419.75USD-8.96%
-1.10 MUSD+22.41%
-896,777.78USD-16.55%
-1.07 MUSD+12.56%
-954,802.47USD-14.11%
-1.11 MUSD+10.47%
-1.01 MUSD-28.12%
-1.40 MUSD+56.67%
-893,530.86USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd, based in Melbourne, Australia, develops regenerative medicine products using mesenchymal lineage cells. The company focuses on clinical-stage therapies such as Remestemcel-L for inflammatory conditions including graft versus host disease and inflammatory bowel disease, and MPC-300-IV for rheumatoid arthritis. It operates in Australia, the US, Singapore, and Switzerland with 81 employees and is listed on the stock exchange since 2015. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

EBITDA per Employee of Mesoblast is -632,716.05 USD in 2026.

EBITDA per Employee of Mesoblast changed from -770,901.23 USD to -632,716.05 USD, representing a -17.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Mesoblast since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Mesoblast historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Mesoblast

All Key Metrics — Mesoblast